Novo Nordisk AS (LTS:0TDD) Short-Term Debt : $1,653 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Novo Nordisk AS Short-Term Debt?

Novo Nordisk AS's Short-Term Debt for the quarter that ended in Dec. 2024 was $1,653 Mil.

Novo Nordisk AS's quarterly Short-Term Debt increased from Jun. 2024 ($786 Mil) to Sep. 2024 ($822 Mil) and increased from Sep. 2024 ($822 Mil) to Dec. 2024 ($1,653 Mil).

Novo Nordisk AS's annual Short-Term Debt increased from Dec. 2022 ($68 Mil) to Dec. 2023 ($776 Mil) and increased from Dec. 2023 ($776 Mil) to Dec. 2024 ($1,653 Mil).

Novo Nordisk AS Short-Term Debt Historical Data

The historical data trend for Novo Nordisk AS's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk AS Short-Term Debt Chart

Novo Nordisk AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Short-Term Debt

Get a 7-Day Free Trial

1,092.98

1,954.41

68.35

776.03

1,653.31

Novo Nordisk AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Short-Term Debt	Get a 7-Day Free Trial															776.03	1,481.68	786.32	821.67	1,653.31

Novo Nordisk AS Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Novo Nordisk AS Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Novo Nordisk AS's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (LTS:0TDD) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

NONOF:USA NVO:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany NVON:Canada N1VO34:Brazil NOV:Bulgaria NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, 2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk AS Headlines

No Headlines